Search research articles
Contact Us
Filters
Showing results (121-130 of 148) with videos related to
Page
of 15
Sort By:
Nature Communications
|
February 14, 2025
The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial
Jaume Mora, Godfrey C F Chan, Daniel A Morgenstern, et al.
Cancers
|
June 24, 2022
Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical Trial
Arif Manji, Yvan Samson, Rebecca J Deyell, et al.
Cancer Immunology, Immunotherapy : CII
|
March 9, 2022
Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial
David M Loeb, Ji Won Lee, Daniel A Morgenstern, et al.
Scientific Reports
|
April 5, 2018
Structure-function analysis and therapeutic efficacy of antibodies to fungal melanin for melanoma radioimmunotherapy
J D Nosanchuk, A Jeyakumar, A Ray, et al.
Pediatric Blood & Cancer
|
July 18, 2018
Risk stratification of high-risk metastatic neuroblastoma: A report from the HR-NBL-1/SIOPEN study
Daniel A Morgenstern, Ulrike Pötschger, Lucas Moreno, et al.
Nature Communications
|
December 8, 2021
Thawing Yedoma permafrost is a neglected nitrous oxide source
M E Marushchak, J Kerttula, K Diáková, et al.
Cell
|
October 18, 1996
Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide
J L Kim, K A Morgenstern, C Lin, et al.
Future Oncology (London, England)
|
March 30, 2018
Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies
Andrew E Place, Kelly Goldsmith, Jean-Pierre Bourquin, et al.
Pediatric Blood & Cancer
|
March 13, 2026
Venetoclax in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors: Results of a Phase 1 Study
Daniel A Morgenstern, Giuseppe Barone, Nadege Corradini, et al.
Cancer Medicine
|
February 24, 2024
Access to innovative therapies in pediatric oncology: Report of the nationwide experience in Canada
Sandra Judd, Gabriel Revon-Riviere, Stephanie A Grover, et al.
Page
of 15
Search research articles
Search
Showing results (121-130 of 148) with videos related to
Sort By:
Page
of 15
Nature Communications
|
February 14, 2025
The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial
Jaume Mora, Godfrey C F Chan, Daniel A Morgenstern, et al.
Cancers
|
June 24, 2022
Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical Trial
Arif Manji, Yvan Samson, Rebecca J Deyell, et al.
Cancer Immunology, Immunotherapy : CII
|
March 9, 2022
Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial
David M Loeb, Ji Won Lee, Daniel A Morgenstern, et al.
Scientific Reports
|
April 5, 2018
Structure-function analysis and therapeutic efficacy of antibodies to fungal melanin for melanoma radioimmunotherapy
J D Nosanchuk, A Jeyakumar, A Ray, et al.
Pediatric Blood & Cancer
|
July 18, 2018
Risk stratification of high-risk metastatic neuroblastoma: A report from the HR-NBL-1/SIOPEN study
Daniel A Morgenstern, Ulrike Pötschger, Lucas Moreno, et al.
Nature Communications
|
December 8, 2021
Thawing Yedoma permafrost is a neglected nitrous oxide source
M E Marushchak, J Kerttula, K Diáková, et al.
Cell
|
October 18, 1996
Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide
J L Kim, K A Morgenstern, C Lin, et al.
Future Oncology (London, England)
|
March 30, 2018
Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies
Andrew E Place, Kelly Goldsmith, Jean-Pierre Bourquin, et al.
Pediatric Blood & Cancer
|
March 13, 2026
Venetoclax in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors: Results of a Phase 1 Study
Daniel A Morgenstern, Giuseppe Barone, Nadege Corradini, et al.
Cancer Medicine
|
February 24, 2024
Access to innovative therapies in pediatric oncology: Report of the nationwide experience in Canada
Sandra Judd, Gabriel Revon-Riviere, Stephanie A Grover, et al.
Page
of 15